C
Cassava Sciences, Inc. (SAVA)
NCM – Real vaqt narxi. Valyuta: USD
2.38
+0.26 (12.26%)
Yopilishda: Mar 10, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
2.38
+0.26 (12.26%)
Yopilishda: Mar 10, 2026, 4:00 PM EDT
Cassava Sciences, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, neyrodegenerativ kasalliklar uchun dori vositalarini ishlab chiqadi. Uning asosiy terapevtik mahsulot nomzodi simufilam, kichik molekulali dori, uning 2-bosqichli klinik sinovi yakunlandi; va tadqiqot diagnostika mahsulot nomzodi SavaDx, Altsgeymer kasalligini aniqlash uchun qon asosidagi biomarker/diagnostika vositasidir. Cassava Sciences, Inc. ilgari Pain Therapeutics, Inc. nomi bilan tanilgan va 2019-yil mart oyida Cassava Sciences, Inc. nomini o'zgartirgan. Kompaniya 1998-yilda tashkil etilgan va Ostin, Texasda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Angélique Bordey Ph.D. | Senior Vice President of Neuroscience |
| Dr. George Thornton Ph.D. | Senior Vice President of Technology |
| Dr. Joseph Hulihan M.D. | Chief Medical Officer |
| Jaren Landen | Chief Clinical Development Officer |
| Mr. Eric J. Schoen | Chief Financial Officer |
| Mr. Jack Moore Ph.D. | Senior Vice President of Clinical Development |
| Mr. Michael Zamloot | Senior Vice President of Technical Operations |
| Mr. R. Christopher Cook J.D. | Chief Operating & Legal Officer |
| Mr. Richard Jon Barry | CEO, President & Director |
| Ms. Freda Nassif | Chief Business Officer & Chief Commercial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2025-12-23 | 8-K | sava20251222_8k.htm |
| 2025-12-22 | 8-K/A | sava20251219_8ka.htm |
| 2025-12-18 | 8-K | sava20251218_8k.htm |
| 2025-12-17 | 8-K | sava20251217_8k.htm |
| 2025-12-03 | 8-K | sava20251201_8k.htm |
| 2025-11-13 | S-3 | forms-3.htm |
| 2025-11-12 | 8-K | f8k_111225.htm |
| 2025-11-12 | 10-Q | sava20250930_10q.htm |
| 2025-10-24 | 8-K | sava20251024_8k.htm |
| 2025-10-22 | 8-K | sava20251020_8k.htm |